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Phosphorylation of a cluster of amino acids in the serum response
factor (SRF) ‘‘MADS box’’I coil DNA binding domain regulated the
transcription of genes associated with proliferation or terminal
muscle differentiation.Mimicking phosphorylation of serine-162, a
target of protein kinase C-, with an aspartic acid substitution
(SRF-S162D) completely inhibited SRF–DNA binding and blocked
-actin gene transcription even in the presence of potentmyogenic
cofactors, while preserving c-fos promoter activity because of
stabilization of the ternary complex via Elk-1. Introduction of
SRF-S162D into SRF null ES cells permitted transcription of the c-fos
gene but was unable to rescue expression of myogenic contractile
genes. Transition of proliferating C2C12 myoblasts to postfusion
myocytes after serum withdrawal was associated with a progres-
sive decline in SRF-S162 phosphorylation and an increase in -actin
gene expression. Hence, the phosphorylation status of serine-162
in the I coil may constitute a novel switch that directs target gene
expression into proliferation or differentiation programs.
PKC  differentiation  -actin  c-fos
Serum response factor (SRF) is a founding member of anancient family of plant and animal DNA-binding proteins,
whose relatives contain a highly conserved DNA-binding
dimerization domain of 90 aa termed the MADS box (1, 2). SRF
is an obligatory transcriptional regulator of two classes of genes.
One class comprises the immediate early genes, typified by c-fos
and Egr1, which are transiently expressed in response to mito-
genic signals (3). The other class comprises a large number of
differentiation genes, typified by the skeletal, smooth, and
cardiac muscle -actins, which are activated in myocytes only
after they cease proliferation and withdraw from the cell cycle
(4, 5). How does SRF play such important roles in both prolif-
eration and differentiation by regulating the transcription of
functionally antagonistic sets of genes?
SRF functions as a master regulatory platform that directs
different gene expression programs through combinatorial in-
teractions with other transcription factors and cofactors. In
replicating myoblasts, SRF recruits proteins having an Ets
domain (Elk-1, Sap1, and Fli) and forms ternary complexes at
the c-fos promoter (6–8). For the most part, Ets factor-
associated ternary complexes do not play a role in regulating
transcription of SRF-dependent myogenic gene targets (9, 10).
Instead, upon serum withdrawal, SRF associates with coacces-
sory transfactors such as Nkx 2.5 (11), GATA4 (12), LIM-only
factor CRP2 (13), myocardin (14–16), MAL (17), and MKL1
and MKL2 (18, 19) to activate transcription of SRF myogenic
target genes, but does so only weakly in replicating myoblasts.
What are the triggers that switch SRF from modulating the
proliferation pathway to modulating the differentiation path-
way? Because SRF isolated from cell extracts is highly phos-
phorylated in numerous sites (20–23), it is possible that site-
specific phosphorylation is a mechanism for regulating the
function of SRF. Thus far, studies of posttranslational modifi-
cations of SRF have yet to reveal specific alterations that actually
control SRF’s ability to switch ‘‘on’’ and ‘‘off’’ myogenic gene
expression. Here, we present a mechanism that facilitates strong
repression of SRF-dependent myogenic differentiation genes
through phosphorylation of a specific, evolutionarily conserved
SRF residue in the MADS box, yet allows for activation of
immediate early proliferation genes.
Results
Aspartate Substitution of Serine-162 in the MADS Box I Coil Abol-
ished SRF-c-fos Promoter DNA Binding. Previous experiments (24)
and data from x-ray crystallographic analysis of SRF’s MADS
box bound to its cognate serum response element (SRE) (ref. 25
and Fig. 1 A and B) directed our attention to two potential
phosphorylation sites (T159 and S162) closely grouped on the I
coil of the MADS box and well conserved across millennia from
yeast to humans (Fig. 1 A–C). A monomer of SRF at S162
contacts T8 andA9 on the C strand, and phosphorylation of S162
was predicted to impede DNA binding directly by phosphate–
phosphate repulsion and steric hindrance (Fig. 1B and T.
Richmond, personal communication). We also noted that T159
did not make a significant contact on the CArG box, hence we
focused on the role of S162 phosphorylation.
Phosphorylation of this residue on the I coil was mimicked
by substitution of S162 with aspartate, and absence of phos-
phorylation was achieved by substitution with alanine at the
same site (Fig. 1D). SRF-S162D completely abolished SRF–
DNA binding (Fig. 1E). In contrast, SRF-S162A decreased
SRF–DNA binding only slightly.
Mimicking Phosphorylation of S162 Blocked Transactivation of Car-
diac -Actin and Smooth Muscle -Actin (SMA) Promoters. We ex-
plored the effects of mimicking phosphorylation of S162 on
transactivation of myogenic genes in the presence or absence of
key coactivators of SRF. We first asked whether disruption of
SRF–DNA binding by SRF-S162D could be overcome by the
presence of Nkx2.5 or GATA4 in the context of -actin pro-
moters. Addition of Nkx2.5 and GATA4 to a suboptimal con-
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centration of SRF led to increased levels of higher-order SRF–
DNA binding complexes, indicating occupation of 3 of the 4
CArG boxes in the cardiac -actin promoter probe (Fig. 2A).
SRF-S162D did not bind to the -actin promoter and did not
form higher-order complexes even with the addition of Nkx2.5
and GATA4 (Fig. 2B), indicating that inhibition of SRF–SRE
binding by S162D cannot be rescued by these coactivators in the
context of the -actin promoter. SRF and S162A synergized with
Nkx2.5 and GATA4 to enhance cardiac -actin transcriptional
activity very strongly in CV1 cells, whereas SRF-S162D greatly
compromised cardiac -actin promoter activity in the presence
of these two coactivators (Fig. 2C). Myocardin alone did not bind
DNA, but in the presence of SRF formed a ternary complex, as
shown by EMSA with both a SMA promoter probe and a cardiac
-actin promoter probe (Fig. 2D). Once again, SRF-S162D
blocked the formation of the ternary complex with myocardin in
the context of both -actin promoters. Consistent with these
effects, wild-type SRF and SRF-S162A synergized with myocar-
din to enhance SMA transcriptional activity strongly, whereas
SRF-S162D greatly compromised transactivation of the SMA
promoter in the presence of myocardin (Fig. 2E).
Mimicking Phosphorylation of S162 in the MADS Box Permitted c-fos
Promoter Activity. We next asked whether the disruption of
SRF–DNA binding by SRF-S162D could be overcome by the
presence of the ternary complex factor Elk-1 in the context of the
c-fos promoter. SRF alone bound to the c-fos SRE probe and
with Elk-1 formed a ternary complex (Fig. 3A). SRF-S162D
displayed markedly diminished binding to the c-fos SRE, but in
the company of Elk-1 was able to form a stable ternary complex.
Mutation of the Ets binding site (EBS)motif adjacent to the c-fos
SRE, to which Elk-1 binds, prevented Elk-1 from rescuing
SRF-S162D–DNA binding, indicating that interaction with
Elk-1 is necessary and sufficient for formation of a ternary
complex involving the c-fos SRE and SRF-S162D. Mutation of
the EBS did not prevent wild-type SRF from forming a ternary
complex with Elk-1 and the SRE. Addition of SRF antibody to
the ternary complex formed between the SRE and either
wild-type SRF or SRF-S162D with Elk-1 caused a supershift to
a slower migrating complex (Fig. 3B). When Elk-1 [activated by
mitogen-activated protein kinase kinase (MEK) and extracellu-
lar regulated kinase (Erk)] was cotransfected with a wild-type
c-fos promoter containing an intact EBS, both wild-type SRF
and SRF-S162D enhanced c-fos promoter activity (Fig. 3C).
However, SRF-S162D in the presence of Elk-1 could not en-
hance transcription of c-fos with a mutated EBS (Fig. 3D). Thus,
SRF-S162D enhanced c-fos transcription, and Ets factor binding
to the SRE and EBS was necessary for this activity.
Introduction of SRF-S162D into SRF Null ES Cells Was Unable to Rescue
the Expression of Muscle Contractile Protein Genes but Permitted the
Activation of Immediate Early Genes. Homozygous SRF
mouse ES cells serve as a cellular model of the knockout animal,
as they are unable to express SRF-dependent myogenic genes
(26). There was no detectable expression of mouse endogenous
SRF in SRF null ES cells (27), as tested by both RT-PCR (Fig.
Fig. 1. SRF MADS box I coil phospho-mimetic mutant SRF-S162D prevents SRF–DNA binding. (A) Schematic crystal structure of the SRF MADS box binding a
CArG box (adapted from refs. 8 and 25) showed one SRF monomer in blue and the other SRF in red. (B) The MADS box I coil contacts the CArG box with
hydrogen-bond interactions shown as solid colored lines and hydrophobic contacts shown as broken colored lines that represent the two SRF monomers.
Complementary DNA strands are labeled W and C. (C) Schematic representation of the MADS box functional regions. (D) Alanine and aspartate substitutions
of the phosphorylatable residues in the MADS box I coil is shown in bold. (E) EMSA with nuclear extracts of CV1 cells transfected with the indicated plasmids.
The DNA probe was a c-fos SRE lacking an EBS. The control was a nuclear extract of cells transfected with empty vector. The arrow indicates the SRF–DNA complex.
Identical results were obtained by using a skeletal -actin SRE-1 probe (data not shown).
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4A) and immunoblot with anti-SRF antibody (Fig. 4B). There
was also a complete block of transcription of both the SRF-
regulated immediate early genes c-fos and Egr-1 and SRF-
regulated terminal differentiation genes, such as the cardiac
-actin, skeletal -actin, SMA, and calponin, in the SRF null ES
cells. Myocardin expression was also absent in these cells.
Transfection of wild-type human SRF into the SRF null ES cells
restored transcriptional activity of these murine SRF gene
targets. Transfection of SRF null ES cells with SRF- S162A also
activated transcription of both c-fos and cardiac -actin genes
(results not shown). SRF-S162D restored transcriptional activity
of the immediate early genes exclusively, that is, only those
SRF-dependent genes that require ternary complex formation
with an Ets factor. None of the SRF-dependent myogenic genes
were transactivated after introduction of the SRF-162D mutant,
indicating that phosphorylation of S162 in theMADS box 1 coil
impedes activation of SRF-dependent myogenic gene programs
without interfering with activation of SRF-dependent prolifer-
ation genes. To solidify this finding, chromatin immunoprecipi-
tation assays were performed in the SRF null ES cells rescued
with SRF or SRF-S162D, with or without Elk-1. The c-fos gene
promoter was bound by SRF and SRF-S162D even without Elk-1
cotransfection, implying that endogenous Elk-1 is sufficient for
induction of c-fos expression by both wild-type SRF and SRF-
S162D (Fig. 4C). However, not even overexpression of Elk-1
could stabilize binding of SRF-S162D to the three myogenic
Fig. 2. SRF phospho-mimetic S162D blocked binding of SRF to -actin
promoters even in the presence of potent cofactors. (A) A subobptimal
amount of wild-type SRF (lane 1) recruited Nkx2.5 and GATA4 and formed
cooperative SRF–DNA binding multimeric complexes (arrowheads, lanes
4–13). Thin arrows indicate Nkx2.5 monomer (third arrow) and dimer (second
arrow). (B) SRF nuclear extract (5 g) formed a SRF–DNA complex with a
32P-labeled cardiac -actin promoter (arrowhead). SRF-S162D did not bind to
the cardiac -actin promoter, even in the presence of Nkx 2.5 and GATA4. (C)
SRF-S162D inhibited activation of the cardiac -actin (CA -actin) promoter,
even in the presence of Nkx2.5 and GATA4. (D) SRF-S162D blocked formation
of the SRF–DNA complexes, as shown by EMSA of nuclear extracts (5 g),
probed with a 32P-labeled cardiac-actin promoter containing four SREs (Left)
or a 32P-labeled SMA promoter containing two SREs (Right). Arrows indicate
the SRF–DNA complex, and arrowheads indicate the ternary complex. (E)
SRF-S162D was unable to activate the SMA promoter even in the presence of
myocardin.
Fig. 3. SRF phospho-mimetic S162D transactivated the c-fos promoter by
forming ternary complexes with an activated Ets factor bound to the adjacent
EBS. (A) EMSA with the c-fos promoter showed that SRF-S162D did not bind to
the c-fos SRE. SRF-S162D did form a ternary complex with a c-fos promoter in
the presence of Elk-1, but not if the Elk-1 EBS had been mutated. Wild-type SRF
formed a ternary complex with the c-fos promoter containing either intact or
mutant EBS. (B) Anti-SRF antibody supershifted ternary complexes formed by
wild-type SRF or SRF-S162D with Elk-1 (arrow). Anti-Elk-1 antibody also su-
pershifted the ternary complex, but much less efficiently than the anti-SRF
antibody. (C) Activated Elk-1 enhanced c-fos promoter activity via endoge-
nous SRF (second control lane), exogenous SRF, and SRF-S162D. CV1 cells
transiently transfected with a luciferase construct under the wild-type c-fos
promoter and the indicated plasmids were treated with PMA for 30 min
before lysis. Bars indicate fold increase in luciferase activity, and asterisks
indicate significant (P0.05) increase over the corresponding basal levels. The
schematic diagram illustrates how SRF could bind to the c-fos SRE and trans-
activate c-fos gene expression despite disruption of direct SRF–SRE binding
caused by phosphorylation of S162. (D) In the presence of activated Elk-1,
wild-type SRF enhanced transcriptional activity of the c-fos promoter bearing
a mutated EBS, whereas SRF-S162D could not. The schematic diagram illus-
trates how c-fos transactivation by S162-phosphorylated SRF in the presence
of Elk-1 was prevented by mutation of the EBS.
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-actin promoters, because these promoters lack an EBS and
hence cannot form a ternary complex with Elk.
PKC Highly Phosphorylated Serine-162. The MADS box I coil
sequence (amino acid 153-NKLRRYTTFSKRKTGIMKKAYE-
LSTL-amino acid 178) contains predicted phosphorylation sites
(ref. 28; NET PHOS 2.0) of several kinases, including PKC isoforms
known to play a role in regulating myogenesis (Fig. 5A). We
generated a phospho-specific antibody targeting SRF-S162-P.
Anti-phospho-S162 (anti-S162-P) detected SRF-S162-P at a
maximum titer of 130,000 and showed minimal crossreactivity
with SRF-T159-P (Fig. 5B). PKC strongly phosphorylated S162
in vitro (Fig. 5C). PKC also phosphorylated T159 in vitro, but
about five times less potently than S162 (data not shown). The
PKC activator phorbol 12-myristate 13-acetate (PMA) increased
SRF-S162 phosphorylation in CV1 cells, as detected by anti-
S162-P antibody (Fig. 5D). PKC-induced SRF-S162 phosphor-
ylation was absent in a mutant SRF with alanine substitutions at
T159, T160, and S162, which also demonstrated that anti-S162-P
does not crossreact with other epitopes on SRF.
Treatmentwith phorbol esters is known to repress cardiac-actin
transcription in primary muscle cultures (29), suggesting a role for
PKC in this phenomenon. To investigate whether the degree of
S162 phosphorylation plays a role in the transition of -actin
transcription from a repressed state to an activated state during the
process of myogenic differentiation, we tracked skeletal -actin
transcript levels in C2C12 cells at various stages after serum
withdrawal. The highest level of SRF-S162 phosphorylation relative
to the total amount of SRF was observed in replicating C2C12 cells
cultured under high serum growth conditions; the level declined as
differentiation progressed through midfusion to postfusion myo-
tubes. The steady decline in the proportion of S162-phosphorylated
SRF in the midfusion and postfusion stages correlated well with
activation of the myogenic gene program, as shown by the appear-
ance of skeletal -actin transcripts (Fig. 5E). Furthermore, activa-
tion of PKC by brief (30 min) exposure to PMA in differentiated
C2C12 cells resulted in a 70- to 100-fold increase in c-fos mRNA
levels (Fig. 5F). This effect was significantly inhibited by single
alanine substitution of S162, indicating that activation of PKC,
whose expression is normally suppressed in differentiated myo-
tubes, is sufficient to induce c-fos expression in differentiated
myotubes, and that phosphorylation of SRF-S162 (and the presence
of the Ets factor) is required for this effect. Collectively, the data
indicate a strong role for S162 phosphorylation (e.g., by PKC
activity) in shifting muscle cells toward the proliferation program
and away from the differentiation program. Thus, SRF-S162 phos-
phorylation reflected a shift toward the proliferation program.
Discussion
A long-standing conundrum in the field of myogenesis concerns
the mechanisms whereby SRF could regulate both replication-
and differentiation-dependent genes with apparent antagonistic
processes. We suggest a model in which phosphorylation of
serine-162 in the SRF MADS box I coil is a key determinant
of the switch in SRF-dependent gene expression between cell
replication and differentiation. The MADS box serves as a
regulatory nexus that mediates interactions between SRF and a
myriad of transcription cofactors, hence differential phosphor-
ylation of MADS box residues could direct specific SRF tran-
scriptional complexes toward the expression of either prolifer-
Fig. 4. Rescue of SRF null ES cells by SRF phospho-mimetic
S162D permitted expression of SRF-regulated immediate early
genes but not of SRF-regulated myogenic gene targets. (A)
Wild-type ES cells expressed the immediate early genes c-fos
and Egr-1, the terminal differentiation myogenic contractile
genes SMA, SM22, calponin, cardiac -actin, and myocardin
and endogenous (mouse) SRF, as shown by RT-PCR of these
transcripts on the indicated days of cell culture (top row). SRF
null ES cells failed to express any of these transcripts (second
row). Introduction of HA-tagged wild-type human SRF in-
duced expression of all of the immediate early genes and
terminal differentiation myogenic contractile genes (third
row). Introduction of HA-tagged SRF-S162D induced expres-
sion only of the immediate early genes (bottom row) but not
of the SRF myogenic gene targets. (B) Immunoblot showing
expression of recombinant wild-type SRF and SRF-S162D after
transfection with the appropriate plasmids into the SRFnull ES
cells used in the chromatin immunoprecipitation (ChIP) assay
shown in C. The control is human SRF overexpressed in wild-
type ES cells; SRF proteins were identified by using anti-SRF
antibody. (C) ChIP showed that SRF phospho-mimetic S162D
could associate with the c-fos promoter in chromatin, but
could not associate with the -actin promoters. Both endog-
enous (lane 3) and exogenous (lane 6) Elk-1 stabilized the
ternary complex with SRF-S162D on the c-fospromoter but did
not stabilize SRF-162D binding to the -actin promoters (lane
6). The schematic diagram shows the promoters of the target
genes; arrows show location of PCR primers flanking the SREs
amplified and electrophoresed on the right.
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ation or differentiation genes. Most SRF accessory proteins that
have been identified as coregulators of c-fos induction are at
endpoints of growth factor-induced signal transduction cascades.
However, the SREs of cardiomyogenic genes recruit different
collateral factors, such as Nkx2.5 and GATA4, that strongly
enhance SRF–DNAbinding affinity, permitting the formation of
higher-order DNA-binding complexes at relatively low SRF
levels (30). Similarly, smooth muscle gene SREs recruit the LIM
protein CRP2, which bridges SRF and GATA factors through
interaction with the MADS I coil (13), and myocardin, which
competes with the Ets factors that interact with the MADS II
coil (16). All of these myogenic cofactors greatly enhance SRF
transactivation activity. Thus, the MADS box region is likely to
be an important site for the receipt of crucial intracellular signals
that enable SRF to recruit specific cofactors to their respective
DNA binding sites.
What are the upstream signals that could induce these func-
tionally important covalent modifications in the MADS box I
coil? The PKC family has been implicated in the control of
proliferation and differentiation of muscle cells (29, 31–33).
Growth factor-stimulated PKC pathways converge on the c-fos
SRE to promote myoblast proliferation (34), and by phosphor-
ylating a conserved site on myogenin, a basic helix–loop–helix
protein, also de-repress the myogenic differentiation program
(35). Capiati et al. (32, 33) have shown that PKC is involved
mainly in the proliferation process inmyoblasts. Phosphorylation
of S162, as mimicked by replacement of this residue by aspartate,
prevents binding of SRF to the c-fos SRE in the absence of an
Ets factor protein, but SRF–SRE binding is restored to normal
in the presence of Elk-1, which forms a ternary complex with
SRF on the c-fos SRE. Wang et al. (16) have demonstrated that
myocardin and the Ets factor Elk-1 compete for interaction with
common sites on the SRF II coil to control smooth muscle gene
expression. This observation supports a model in which growth
factor stimulation leads to phosphorylation of S162 in the
MADS box in a manner that suppresses the expression of muscle
differentiation genes, while coordinately permitting or increas-
ing the association between Ets factors and SRF to up-regulate
c-fos transcription. This model is also supported by the present
data from the SRF null ES cell ‘‘rescue’’ experiments. Upon
transfection with wild-type SRF or SRF-S162D, the SRF null ES
cells express only the proliferation program genes, such as c-fos
and Egr1, whereas the expression of muscle differentiation
genes, such as the cardiac -actin, skeletal -actin, and SMA,
Fig. 5. PKC strongly phosphorylated SRF serine-162. (A) Candidate protein kinases and their consensus phosphorylation sites on the 1 coil as predicted by
the NETPHOS 2.0 program. (B) Potency and crossreactivity of affinity-purified SRF-S162-P antibody against nonphosphorylated and SRF-T159- or SRF-S162-
phosphorylated I coil peptides. ELISA was used to measure potency and crossreactivity, as shown by the dilution titer of the antibodies. (C) In vitro
phosphorylation of GST-SRF (residues 1–171) by purified PKC, PKA, casein kinase I (CKI), and Ca2calmodulin-dependent PK II (CaMKII). Immunoblots were
probed with anti-SRF-S162-P. (D) PKC phosphorylated the MADS box I coil in vivo. Shown are immunoblots of lysates of CV1 cells expressing PKCwith empty
vector, wild-type SRF (wtSRF), or SRF with triple alanine substitutions for T159, T160, and T162 (tmSRF), with or without the addition of PMA, immunoprecipitated
with HA-epitope antibody, and probed with anti-SRF or anti-SRF-S162-P. (E) SRF-S162 phosphorylation was highest during myoblast proliferation and declined
during differentiation. (Top) Immunoblots of nuclear extracts of C2C12 myoblasts during replication (prefusion), shortly after withdrawal from replication
(midfusion), and after terminal differentiation (postfusion). (Middle) Quantification of band intensity by densitometry, using the IMAGE QUANT 5.2 program. The
y axis corresponds to the pixel value of the bands shown in Top, displayed as a ratio of immunoblottable SRF-S162-P to total SRF. (Bottom) The appearance of
skeletal -actin mRNA, indicated by blots of RNA isolated from C2C12 cells during myogenesis with a skeletal -actin cDNA probe, correlated with the decline
of SRF-S162 phosphorylation. (F) Endogenous c-fosmRNA levels were low in postdifferentiation C2C12 myotubes but increased after activation of PKC by 30 min
of exposure to PMA; the effect of PMA was markedly blunted by preventing phosphorylation of S162 (i.e., S162A). These results are representative of two
separate experiments.
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remain suppressed. Thus, phosphorylation of the highly con-
served serine-162 residue in the I coil of the SRF MADS box
represents another pathway that regulates SRF activity to mod-
ulate gene expression during cellular replication and differen-
tiation. This mechanism is a key element in a novel switch that
could direct target gene expression into proliferation or differ-
entiation programs.
Experimental Procedures
Expression Vectors and Reporter Genes. The luciferase reporter
plasmids for -actin gene promoters and SRF expression vectors
have been described (13). The c-fos promoter construct
(pwtGL3) and the mutant c-fos promoter (ppm18GL3) were
gifts of Ron Prywes (Columbia University, New York; ref. 36).
SRF MADS box mutants were made by PCR mutagenesis and
cloned into the pCGN vector as described (24). Construction of
a GST mouse myocardin fusion protein in pGEX-4T-1 was as
described (14). Maltose binding protein-tagged Nkx2.5 and
GATA4 constructs were as described (37). pCMV5 Elk-1 and
the Elk-1-histidine fusion protein DNA vectors were provided by
Peter Shaw (University of Nottingham, Nottingham, U.K.) and
Andrew Sharrocks (University of Manchester, Manchester,
U.K.). Metallothionein-PKC was from Stuart Yuspa (National
Cancer Institute, Bethesda). The PKA clone, MT-CEVa, was
from Stanley McKnight (University of Washington, Seattle).
MEK-1 and Erk-1 in the vector pMT3-HA were from Zhijun
Luo (Boston University Medical Center, Boston). GST-SRF
(amino acid residues 1–171) in pGEX 4T3 was as described (24).
Phosphorylation of the SRF MADS Box, Assayed by Phospho-Specific
Antibodies. Synthesis of anti-SRF peptide antibody, anti–SRF
threonine 159 phospho-specific antibody, and anti-SRF serine-
162 phospho-specific antibody have been described (24). Briefly,
the antibodies were raised in rabbits against the following
peptides representing amino acids 152–169 of SRF, DNKLR-
RYTTFSKRKTGIM, DNKLRRYT(-PO4)TFSKRKTGIM,
and DNKLRRYTTFS(-PO4)KRK TGIM (Bethyl Laboratories,
Montgomery, TX), and affinity-purified before use. PKC or
empty vector was cotransfected with pCGN, wild-type SRF, or
triple-alanine mutant SRF (SRF-T159ASRF-T160ASRF-
S162A) into CV1 cells by using Lipofectamine (Invitrogen)
according to the manufacturer’s protocol. The cells were treated
with 100 nM PMA for 30 min before cell lysis in buffer
containing 50 mM TrisCl (pH 7.5), 500 mM NaCl, 0.5% Triton
X-100, 2 mM sodium vanadate, 50 mM NaF, and protease
inhibitors. Recombinant hemagglutinin (HA)-tagged SRF pro-
teins were immunoprecipitated from clarified lysate by using
12CA5 antibody (Roche Applied Science), subjected to SDS
PAGE, and immunoblotted by using anti-SRF peptide antibody
or anti-SRF-S162-P.
Preparation of Nuclear Extracts and EMSAs. Nuclear fractions were
prepared according to the protocol of Dignam et al. (38), and
some cells were treated with PMA (100 nM) before harvest.
Nuclear preparations contained 50 mM sodium fluoride and 2
mM sodium vanadate as phosphatase inhibitors and were nor-
malized for protein concentration. For SRF–DNA binding in
EMSA, the following DNA probes were used: cardiac -actin
complete promoter, nucleotides 315 to 58; c-fos SRE, ACA-
CAGGATGTCCATATTAGGACATCTGC; c-fos SRE lacking
the complete EBS GGATGTCCATATTAGG; c-fos SRE with
EBS mutation, ACACcGGcTGTCCATATTAGGACATC-
TGC; SMA, nucleotides141 to1; and skeletal -actin SRE1
nucleotides 98 to 76. Purified Elk-1 protein was first phos-
phorylated by using p42 mitogen-activated protein kinase or
Erk-1 andMEK-1 in the presence of 1 mM cold ATP. EMSAwas
performed as described (13, 24).
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